Related references
Note: Only part of the references are listed.Erenumab versus topiramate for the prevention of migraine - a randomised, double-blind, active-controlled phase 4 trial
Uwe Reuter et al.
CEPHALALGIA (2022)
Small molecule CGRP receptor antagonists for the preventive treatment of migraine: A review
Jessica Barreto Ribeiro dos Santos et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2022)
European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention-2022 update
Simona Sacco et al.
JOURNAL OF HEADACHE AND PAIN (2022)
GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016 (vol 17, pg 954, 2018)
Ali H. Mokdad
LANCET NEUROLOGY (2021)
Efficacy and safety of anti-calcitonin gene-related peptide monoclonal antibodies for treatment of chronic migraine: A systematic review and network meta-analysis
Prashant Soni et al.
CLINICAL NEUROLOGY AND NEUROSURGERY (2021)
Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial
Robert Croop et al.
LANCET (2021)
Efficacy and Safety of Monoclonal Antibody Against Calcitonin Gene-Related Peptide or Its Receptor for Migraine: A Systematic Review and Network Meta-analysis
Xing Wang et al.
FRONTIERS IN PHARMACOLOGY (2021)
Randomised, controlled trial of erenumab for the prevention of episodic migraine in patients from Asia, the Middle East, and Latin America: The EMPOwER study
Shuu-Jiun Wang et al.
CEPHALALGIA (2021)
The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice
Jessica Ailani et al.
HEADACHE (2021)
Efficacy and safety of fremanezumab for episodic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients
Fumihiko Sakai et al.
HEADACHE (2021)
Efficacy and safety of fremanezumab for chronic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients
Fumihiko Sakai et al.
HEADACHE (2021)
Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study
Takao Takeshima et al.
HEADACHE (2021)
Efficacy of calcitonin gene-related peptide (CGRP) receptor blockers in reducing the number of monthly migraine headache days (MHDs): A network meta-analysis of randomized controlled trials
Ahmed Taher Masoud et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2021)
Diagnosis and management of migraine in ten steps
Anna K. Eigenbrodt et al.
NATURE REVIEWS NEUROLOGY (2021)
Atogepant for the Preventive Treatment of Migraine
Jessica Ailani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine - an updated systematic review and meta-analysis
Hong Deng et al.
BMC NEUROLOGY (2020)
Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)
Messoud Ashina et al.
CEPHALALGIA (2020)
Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2
Richard B. Lipton et al.
NEUROLOGY (2020)
Guidelines for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults
Hans-Christoph Diener et al.
CEPHALALGIA (2020)
Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention
J. Schoenen et al.
REVUE NEUROLOGIQUE (2020)
CGRP inhibitors for migraine prophylaxis: a safety review
Eduardo Rivera-Mancilla et al.
EXPERT OPINION ON DRUG SAFETY (2020)
Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial
Wim M. Mulleners et al.
LANCET NEUROLOGY (2020)
Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial
Peter J. Goadsby et al.
LANCET NEUROLOGY (2020)
Migraine remains second among the world's causes of disability, and first among young women: findings from GBD2019
T. J. Steiner et al.
JOURNAL OF HEADACHE AND PAIN (2020)
Targeting CGRP for the Prevention of Migraine and Cluster Headache: A Narrative Review
Hsiangkuo Yuan et al.
HEADACHE (2019)
Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial
Michel D. Ferrari et al.
LANCET (2019)
RoB 2: a revised tool for assessing risk of bias in randomised trials
Jonathan A. C. Sterne et al.
BMJ-BRITISH MEDICAL JOURNAL (2019)
CGRP, a target for preventive therapy in migraine and cluster headache: Systematic review of clinical data
Sabrina Khan et al.
CEPHALALGIA (2019)
Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial
Vladimir Skljarevski et al.
CEPHALALGIA (2018)
Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults
Cristina Tassorelli et al.
CEPHALALGIA (2018)
ARISE: A Phase 3 randomized trial of erenumab for episodic migraine
David W. Dodick et al.
CEPHALALGIA (2018)
Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition
Jes Olesen
CEPHALALGIA (2018)
Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine A Randomized Clinical Trial
David W. Dodick et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Evaluation of Galcanezumab for the Prevention of Episodic Migraine The EVOLVE-1 Randomized Clinical Trial
Virginia L. Stauffer et al.
JAMA NEUROLOGY (2018)
Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study
Uwe Reuter et al.
LANCET (2018)
Galcanezumab in chronic migraine The randomized, double-blind, placebo-controlled REGAIN study
Holland C. Detke et al.
NEUROLOGY (2018)
Global, regional, and national burden of meningitis, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016
Joseph Raymond Zunt et al.
LANCET NEUROLOGY (2018)
Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016
Lars Jacob Stovner et al.
LANCET NEUROLOGY (2018)
Blocking CGRP in migraine patients - a review of pros and cons
Marie Deen et al.
JOURNAL OF HEADACHE AND PAIN (2017)
Fremanezumab for the Preventive Treatment of Chronic Migraine
Stephen D. Silberstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
A Controlled Trial of Erenumab for Episodic Migraine
Peter J. Goadsby et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Rayyan-a web and mobile app for systematic reviews
Mourad Ouzzani et al.
SYSTEMATIC REVIEWS (2016)
Reduce dimension or reduce weights? Comparing two approaches to multi-arm studies in network meta-analysis
Gerta Ruecker et al.
STATISTICS IN MEDICINE (2014)
The International Classification of Headache Disorders, 3rd edition (beta version)
Andre Bes et al.
CEPHALALGIA (2013)
Visualizing the flow of evidence in network meta-analysis and characterizing mixed treatment comparisons
Jochem Koenig et al.
STATISTICS IN MEDICINE (2013)
Network meta-analysis, electrical networks and graph theory
Gerta Ruecker
RESEARCH SYNTHESIS METHODS (2012)
Bias and efficiency of meta-analytic variance estimators in the random-effects model
W Viechtbauer
JOURNAL OF EDUCATIONAL AND BEHAVIORAL STATISTICS (2005)
What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data
MJ Sweeting et al.
STATISTICS IN MEDICINE (2004)
Placebo effect in the acute treatment of migraine: subcutaneous placebos are better than oral placebos
AJM de Craen et al.
JOURNAL OF NEUROLOGY (2000)
Share Paper
